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High-risk mucosotropic Human papillomaviruses (HPVs), especially HPV-16, are the aetiological agents
of cervical cancer and the cellular targets of their E6 oncoproteins have been much studied. However,
much less is known about the cellular targets of the cutaneous HPV E6 proteins. In this study, a
proteomic analysis of cells transfected with the E6 proteins from cutaneous HPV types speciﬁcally
identiﬁed E6-interacting proteins involved in the ubiquitination pathways. These include the E3
ubiquitin-protein ligases E6AP and UBR4/p600. We also show that E6AP can contribute towards the
steady-state levels of E6 and, conversely, that certain E6 proteins, in addition to those derived from the
high-risk mucosal HPV types, can enhance levels of E6AP turnover. These results deﬁne important
differences and commonalities in how HPV E6 proteins of mucosal and cutaneous origin interact with
cellular ubiquitin-protein ligases.
& 2012 Elsevier Inc. All rights reserved.Introduction
Human papillomaviruses (HPVs) are small DNA viruses that
infect epithelial tissue and whose life cycles depend upon the
differentiation programme of the epithelium. More than 100
different HPV types have been described and they have very
diverse anatomical sites of infection. HPVs are found in the alpha,
beta and gamma branches of the papillomavirus phylogenetic
tree (de Villiers et al., 2004; Bouvard et al., 2009) The mucoso-
tropic HPV types are found in the alpha group and are generally
referred to as high-risk or low-risk, depending upon their associa-
tion with anogenital malignancies, including cervical cancer. The
high-risk HPV-16, for example, is the causative agent of approxi-
mately 70% of all cases of cervical cancer. E6 oncoproteins from
the high-risk mucosotropic HPV types can induce the degradation
of certain cellular target proteins, such as the p53 tumour sup-
pressor and the apoptosis-inducing Bak protein, through inter-
action with the E6AP ubiquitin-protein ligase (Huibregtse et al.,
1993; Scheffner et al., 1993; Thomas and Banks, 1998; Liu and
Baleja, 2008). They also induce the degradation of PDZ-containing
substrates, possibly in an E6AP-independent manner (for review,




.mucosotropic HPV types had also been shown to interact with
E6AP, albeit with much lower afﬁnity (Storey et al., 1998; Brimer
et al., 2007), although their target proteins, apart from Bak
(Thomas and Banks, 1999), are as yet unknown. In addition, Pim
et al. (2002) had shown that E6s from low-risk mucosotropic HPV
types could induce the degradation of PDZ-containing proteins, if
they were provided with a PDZ-binding domain, whereas cuta-
neous E6 proteins could not. Certain cutaneous HPV E6 proteins
also interact with Bak (Jackson et al., 2000; Leverrier et al.,2007;
Underbrink et al., 2008) and with p300 (Mu¨ller-Schiffmann et al.,
2006; Muench et al., 2010) whose degradation they enhance
(Howie et al., 2011). To further investigate the cellular targets of
the cutaneous HPV E6 proteins we initiated a proteomic analysis.Results
Proteomic analysis of cutaneous HPV E6 proteins
In comparison with the mucosotropic HPV E6 proteins, less is
known about the cellular partners of the E6 proteins from cuta-
neous HPV types. Therefore we performed a proteomic analysis of
their potential cellular binding partners. To do this, we transfected
293 cells with plasmids expressing HA-tagged E6 proteins from the
cutaneous beta types HPV-8, HPV-24 and HPV-38, and cutaneous
alpha type HPV-10. High-risk mucosotropic alpha type HPV-16 E6
and empty vector were included as controls. After 24 h the soluble
proteins were extracted from the cells with lysis buffer, and
the lysates were incubated on a rotating wheel for 3 h at 4 1C with
Table 1
Highest-ranking cellular protein speciﬁcally pulled down by each HPV E6 protein.
By comparison with pulldown from cells transfected with empty vector.
HPV E6 Protein pulled
down
Log (e) No. of peptides
HPV-8 p300 245.1 22/26
HPV-10 E6-AP 125.1 12/12
HPV-24 E6-AP 47.0 6/6
HPV-38 UBR4/p600 90.5 11/11
HPV-16 E6-AP 41.8 4/4
Log (e): the base-10 log of the expectation that any particular protein assignment
was made at random (E-value). No. of peptides: the number of different peptides
found for this protein/the total number found for this protein.
Fig. 1. E6AP levels in the presence of E6. Western blots of HEK293 cells
transfected with E6AP wild type (upper panel) or c4a mutant (lower panel),
either alone (C) or with the E6 proteins from HPV 8, 12, 14 and 24 (beta types) and
HPV 10, 11 and 16 (alpha types). Blots were probed with anti-E6AP antibody plus
anti-b-galactosidase (LacZ) as control.
M. Thomas et al. / Virology 435 (2013) 357–362358anti-HA antibody immobilised on agarose beads (EZEView, Sigma).
After extensive washing and removal of detergent, the beads were
subjected to tryptic digest and mass spectroscopy.
The pulldown proﬁle of each E6 protein was compared with
that of the empty vector pulldown, to eliminate non-speciﬁc
protein interactions, and the highest-ranked, speciﬁcally pulled-
down protein for each E6 is shown in Table 1. In each case, the
relevant E6 protein was detected, albeit at low levels. A positive
control for the assay was provided by the HPV-8 E6, whose
highest afﬁnity pulldown partner was p300, which has been
previously published to be a speciﬁc interacting partner of HPV-8
E6 (Mu¨ller-Schiffmann et al., 2006; Muench et al., 2010; Howie
et al., 2011). The highest afﬁnity pulldown partner of HPV-38 E6
was the UBR4 ubiquitin ligase, also known as p600, which has
been shown to be targeted by the E7 proteins of HPV-16, HPV-6b,
HPV-11 and bovine papillomavirus (BPV-1) (Huh et al., 2005;
DeMasi et al., 2005). Another ubiquitin ligase, E6AP was the
highest afﬁnity pulldown partner of both HPV-10 and HPV-24 E6.
E6AP was ﬁrst described as an important cellular partner of the
high-risk mucosotropic HPV E6 proteins, and it was initially
thought to be an interaction speciﬁc to cancer-related HPV types
(Huibregtse et al., 1993; Scheffner et al., 1993). However, the low
risk HPV 11E6 has since been shown to also interact with E6AP
(Storey et al., 1998; Brimer et al., 2007). Since the interactions
between high-risk mucosal HPV E6 proteins and E6AP had been
shown to affect the levels of each protein in vivo (Kao et al., 2000;
Tomaic´ et al., 2009a), it was clearly of interest to determine the
possible functions of this interaction in the case of cutaneous HPV
E6 proteins.
E6AP protein levels in the presence of E6 in vivo
It has long been known that HPV-16 E6 can induce the
proteasomal degradation of E6AP (Kao et al., 2000), so we ﬁrst
investigated the stability of E6AP in the presence of E6 proteins
from a range of HPV types. HEK293 cells were transfected with a
plasmid expressing the E6AP wild type or the c4amutant, which
is catalytically inactive (Huibregtse et al., 1995), plus plasmids
expressing a series of HPV E6 proteins. After 24 h the cells were
harvested and the cell extracts analysed by SDS-PAGE and
Western Blot. The blots were probed with anti-E6AP antibody
and the results are shown in Fig. 1, and as can be seen the levels of
E6AP are reduced in the presence of the alpha type HPV E6
proteins 10, 11, 16; but not in the presence of the beta type HPV
E6 proteins 8, 12, 14, 24, 38. Interestingly, the c4a mutant
responds very similarly to the wild type, which is consistent with
previous reports implicating recruitment of endogenous wild type
E6AP to direct the degradation of this mutant (Kao et al., 2000).
It was possible that the reduction in E6AP levels seen with the
alpha type HPV E6 proteins was caused by proteasomal degra-
dation of the E6AP protein, or alternatively that the E6AP wasrelocated into an insoluble fraction of the cell. To address these
possibilities, we repeated the transfection and western blot with
E6AP and the HPV-10, HPV-11 or HPV-16 E6 proteins, including
proteasome inhibitors. We also analysed E6AP levels in both the
E1a extract (‘‘soluble fraction’’) and in the residue (‘‘insoluble
fraction’’).
The results are shown in Fig. 2, where it can be seen that the
levels of E6AP in the insoluble fraction are extremely low and do
not change in the presence of HPV-10, HPV-11 or HPV-16 E6, with
or without proteasome inhibition. Thus, the changes seen in E6AP
levels do not appear to be caused by relocation of the protein.
It can also be seen in the soluble fraction that proteasome
inhibition can rescue the reduction in E6AP levels caused by HPV-16
E6, as might be expected from previous reports (Kao et al., 2000).
Interestingly, the HPV-11 E6-induced reduction of E6AP is also
rescued to a certain extent, but the HPV-10 E6 effect upon E6AP
levels appears to be, at least in part, proteasome-independent.
Half life of E6AP in the presence of E6
Clearly, the presence of HPV-10 and HPV-11 E6 resulted in lower
levels of E6AP in the cell, and we wished to determine whether this
was the result of increased turnover of E6AP protein, as is the case
with the high-risk HPV-16 and HPV-18 E6s. To address this, we
performed a half-life assay, using E6AP-null cells to reduce any
potential interference with endogenous E6AP (Massimi et al., 2008;
Tomaic´ et al., 2009a). Brieﬂy, cells were transfected with E6AP either
alone or together with HPV-10 E6 or HPV-11 E6. After 24 h the cells
were treated with cycloheximide at 50 mg/ml in DMSO to block
further protein synthesis. The cells were harvested at 0, 2, 4, 7,
14 and 21 h post-treatment and the levels of E6AP analysed by
SDS-PAGE and western blot. The results are shown in Fig. 3, where it
can be seen that the half-life of E6AP in the absence of E6 is between
14 and 21 h, as reported previously (Tomaic´ et al., 2011). It is also
clear that the half-life of E6AP is reduced to approximately 2 h in the
presence of HPV-10 E6 and around 7 h with HPV-11 E6. Thus,
the reduction in E6AP levels seen in the presence of HPV-10 and
HPV-11 E6 proteins (Figs. 1 and 2) would appear to be the result of
destabilisation of the E6AP protein.
E6AP stability in the presence of E6 in vitro
Having shown that the E6 proteins from HPV-10, HPV-11
and HPV-16 could induce the degradation of exogenous E6AP in
Fig. 2. Effect of proteasome inhibition upon E6-induced reduction of E6AP levels. Western blots of HEK293 cells transfected with E6AP wild type or c4a mutant, together
with the indicated E6 proteins. Prior to harvesting the transfected cells were treated with proteasome inhibitors CBZ and LLnL (CBZ) for 2 h. Blots were probed with anti-
E6AP antibody plus anti-b-galactosidase (LacZ) as control.
Fig. 3. E6AP half-life is reduced in the presence of HPV-10 and HPV-11 E6
proteins. E6AP-null cells were transfected with plasmids expressing E6AP and
either HPV-10 E6 or HPV-11 E6. After 24 h the cells were treated with cyclohex-
imide, harvested at the times indicated, and analysed by SDS-PAGE and Western
blot. Blots were probed with anti-E6AP antibody plus anti-b-galactosidase (LacZ)
as control.
Fig. 4. E6AP stability in the presence of E6 in vitro. In vitro translated radi-
olabelled E6AP protein was mixed with water-primed lysate (), or with in vitro
translated radiolabelled E6 protein as indicated and incubated for 6 h at 30 1C,
then anaysed by SDS-PAGE and autoradiography.
Fig. 5. Binding of E6 proteins to E6AP in vitro. In vitro translated, radiolabelled E6
protein, as indicated, was mixed with GST alone or with GST-E6AP fusion protein
immobilised on glutathione agarose (Sigma) and incubated at 4 1C for 2 h, then
washed extensively and analysed by SDS-PAGE and autoradiography. The upper
panels show the autoradiographs; the lower panels show the Coomassie-
stained gel.
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induce its degradation in vitro. To address this, we performed an
in vitro degradation assay. In vitro translated radiolabelled E6AP
protein was mixed with water primed lysate, or with in vitro
translated HPV-10, HPV-11 or HPV-16 E6 and incubated at 30 1C
for 6 h, then analysed by SDS-PAGE and autoradiography. The
results in Fig. 4 clearly show that HPV-16 E6 induces signiﬁcant
degradation of E6AP in vitro; no degradation is seen with HPV-11
E6 and a very slight reduction of E6AP levels is seen with
HPV-10 E6.
Binding of E6 proteins to E6AP in vitro
It was clear from the assays both in vitro and in vivo that the
E6 proteins do not interact identically with E6AP. To examine the
binding activities in more detail, we performed in vitro binding
assays with either GST alone, or GST-E6AP and in vitro translated
HPV E6 proteins. The results of these assays are shown in Fig. 5,
where it can be seen that HPV-16 E6 binds strongly to GST-E6APand HPV-11 E6 binds weakly in vitro, as would be expected from
previous studies (Storey et al., 1998; Brimer et al., 2007). The
HPV-10 and HPV-38 E6 proteins bind strongly to the GST-E6AP,
whereas the HPV-24 E6 scarcely binds E6AP at all in vitro. This is
in interesting contrast to the results from the pulldown assay in
which HPV-24 E6 bound strongly to E6AP, and HPV-38 E6 did not
bind E6AP, the latter of which is in agreement with previous
studies (White et al., 2012). This suggests that there may be
proteins, or protein modiﬁcations, involved in the in vivo binding
Fig. 6. HPV-38E6 binds UBR4/p600 in vitro. In vitro translated, radiolabelled UBR4/
p600 protein was mixed with GST alone, GST-11E7, GST-10E6 or GST-38E6 fusion
protein immobilised on glutathione agarose (Sigma) and incubated at 4 1C for 2 h,
then washed extensively and analysed by SDS-PAGE and autoradiography. The
upper panels show the autoradiographs; the lower panels show the Coomassie-
stained gel.
Fig. 7. E6AP stabilises E6 in vivo. Western blot of HEK293 cells transfected with
the indicated HA-tagged E6s, either alone, with wild-type E6AP or with the c4a
mutant of E6AP. The blot was probed with anti-HA antibody, plus antib-
galactosidase (LacZ) as control. The HA-tagged E6 proteins are arrowed.
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translated protein preparation.
A strong interacting partner of HPV-38 E6 in vivo appeared to
be UBR4/p600 (Table 1). UBR4/p600 had been shown to interact
with the E7 proteins of HPV-16, HPV-6b, HPV-11 and bovine
papillomavirus (BPV-1) (Huh et al., 2005; DeMasi et al., 2005), but
no interaction with an HPV E6 protein had been conﬁrmed.
To investigate this we performed an in vitro binding assay, using
in vitro translated, radiolabelled UBR4/p600 and GST alone, GST-
11E7 as positive control, GST-10E6, and GST-38E6. The results are
shown in Fig. 6, where it can be seen that UBR4/p600 binds to
GST-38E6 at a comparable level to its binding of GST-11E7, thus
conﬁrming the results of the proteomic analysis.
E6AP stabilises E6 proteins in vivo
Previous studies have shown that one consequence of the
interaction between HPV E6 and E6AP is stabilisation of the E6
protein (Tomaic´ et al., 2009a). To investigate the effects of E6AP
upon the expression levels of HPV-10 and HPV-24 E6, we
transfected 293 cells with vectors expressing HA-tagged HPV-10
and HPV-24 E6 proteins, with or without a vector expressing
either wild type E6AP, or the c4a mutant of E6AP. After 24 h we
analysed the E6 proteins by SDS-PAGE and western blotting and
the results are shown in Fig. 7. It can clearly be seen that the
levels of HPV-24 E6 markedly increase in the presence of both
wild-type and mutant E6AP, while HPV-10 E6 levels are some-
what increased with wild-type E6AP, and strongly increased in
the presence of the catalytically-defective mutant of E6AP. It had
previously been shown that the HPV-16 and HPV-18 E6s were
stabilised in the presence of E6AP (Tomaic´ et al., 2009a), and our
ﬁnding that taxonomically diverse cutaneous HPV E6 proteins are
also stabilised suggests that interaction with E6AP is a means of
stabilising the E6 protein that is common to many HPV types.Discussion
A protein pulldown assay with the E6 proteins from a number
of evolutionarily diverse HPV types was used as a starting point to
investigate their potential cellular protein-binding partners.
The pulldown was validated by the strong pulldown of p300 by
HPV-8 E6 (Mu¨ller-Schiffmann et al., 2006; Muench et al., 2010)
and E6AP with HPV-16 E6. The pulldown of E6AP with both
HPV-10 and HPV-24 E6 proteins was somewhat surprising, in that
no ubiquitin/proteasomal activities had previously been asso-
ciated with the E6 proteins of these virus types, but the
co-pulldown of several proteasome subunits (data not shown)
in each case further validated the result. The pulldown of UBR4/
p600 with HPV-38 E6 was also surprising, since previous reports
had shown UBR4/p600 to be targeted by E7 proteins rather than
E6. (Huh et al., 2005; DeMasi et al., 2005). In fact, a recent
proteomic analysis also suggests that HPV-38 E6 might bind
UBR4/p600, but that observation was not validated (White
et al., 2012), Here we have shown that the GST HPV-38 E6 can
bind to in vitro translated UBR4/p600 as strongly as its known
interactor, HPV-11 E7. No signiﬁcant binding is seen with HPV-10
E6, indicating that this interaction may be speciﬁc to HPV-38 E6.
Possibly certain beta-type HPVs, such as HPV-38, target UBR4/
p600 mainly through their E6 protein, similar to the case of
Rhesus papillomavirus which targets polarity proteins through a
PDZ-binding motif on the E7 protein, rather than on the E6, as in
high-risk HPV types (Tomaic´ et al., 2009b).
We have shown here that E6AP can interact with diverse alpha
and beta type HPV E6 proteins, regardless of their cancer
association, and that this interaction can increase the steady-
state levels of those E6 proteins. However there are clear
differences in the effects of the interaction upon the E6AP protein.
Half-life analyses show that the E6 proteins of alpha HPV-10,
HPV-11 (Fig. 3) and HPV-16 (Kao et al., 2000) can all reduce the
stability of E6AP in vivo, whereas the ability to induce E6AP
degradation in vitro appears to be restricted to the high-risk alpha
HPV-16 E6 with only weak activity seen with HPV-10 E6. In
addition, only the HPV-16 E6-induced degradation of E6AP is
signiﬁcantly blocked by proteasome inhibition, which is consis-
tent with the ﬁndings of Kehmeier et al. (2002). Thus, it would
seem that the low risk alpha E6 proteins can induce the degrada-
tion of a target protein, but in a manner different from the high-
risk alpha E6s. This supports the conclusions of Pim et al. (2002),
who found that low-risk HPV E6 proteins could induce the
degradation of PDZ-containing proteins when supplied with a
PDZ-binding motif in the form of a chimæric tail.
From the proteomic analysis it was clear that the various E6s
interacted to different degrees with E6AP; in GST pulldown assays
with in vitro translated E6 proteins these differences were more
marked. HPV-11 E6 bound GST-E6AP more weakly than HPV-16
E6, as might have been expected from previously published data
(Storey et al., 1998; Kao et al., 2000; Brimer et al., 2007). However
HPV-10 E6 and HPV-38 E6 proteins both bound as strongly as the
HPV-16, while HPV-24 E6 barely bound GST-E6AP in vitro. This
was in contrast to the results from the mass spectroscopy, in
which HPV-24 E6 bound strongly to E6AP, while HPV-38 E6 did
not. This may suggest that the HPV-24 E6 is subject to post-
translational modiﬁcations that enhance E6AP interaction,
but which do not occur in the reticulocyte lysate translation
system. This is supported by the fact that, as can be seen from
Figs. 5 and 7, the in vitro translated HPV-24 E6 runs with slightly
greater mobility than the other E6 proteins, whereas in vivo it
runs much more slowly. The discrepancy between the in vitro and
in vivo results with HPV-38 E6 is harder to explain, but one
intriguing possibility is competition between UBR4/p600
and E6AP for the same site of interaction on HPV-38 E6. Since
M. Thomas et al. / Virology 435 (2013) 357–362 361UBR4/p600 appears to be a very strong interactor in the proteo-
mic analysis, this may explain why E6AP is only bound in the
in vitro assay.
Finally, we show that in the presence of E6AP the stability of
the HPV-10 and HPV-24 E6 proteins is enhanced. This is consis-
tent with the ﬁndings of Tomaic´ et al. (2009a) who had shown
similar enhanced stability of the high risk mucosotropic HPV-16
and HPV-18 E6 proteins. However, regardless of the strength with
which the different E6 proteins appear to target E6AP for
degradation, the effects on E6 stability appear similar. This raises
the issue of how a protein that is being degraded by E6 can
nonetheless enhance E6 stability. However, many protein-protein
interactions can result in active protein stabilisation. This can be
through chaperone-like activity (DeFee et al., 2011) or in the case
of proteasome-linked activity, by potential protection at the site
of the proteasome itself (Coleman et al., 2003). Current studies
aim to elucidate which of these possiblities is the most likely for
the E6-E6AP complex.Materials and methods
Cells
The cells used were HEK293 cells, maintained in Dulbecco’s
modiﬁed medium supplemented with 10% foetal calf serum.
Plasmids and transfections
The plasmids expressing HA-tagged E6 proteins and the
untagged E6 proteins for in vitro expression have been described
previously (Massimi et al., 2008), as have the plasmids expressing
wild type and mutant E6AP and GST-E6AP (Tomaic´ et al., 2009a).
The plasmid expressing V5-tagged UBR4/p600 was the kind gift of
Dr Takafumi Tasaki.
Transfections were done using the standard calcium phos-
phate precipitation method (Wigler et al., 1979) and the cellular
proteins were extracted in E1a buffer after an overnight incuba-
tion, as described previously (Thomas et al., 2002)
Western blots and antibodies
Western blots were performed on cell extracts as described
previously (Massimi et al., 2008). The primary antibodies
used were anti-HA (Roche) at 1/1000 and anti-b-galacto-
sidase (Promega) at 1/5000 and anti-E6AP (BD Biosciences) at 1/
1000; HRP-conjugated secondary antibodies (DAKO) were used as
appropriate.
In vitro translation and degradation assays
Proteins were translated in vitro using the Promega TnT
in vitro translation kit according to the manufacturer’s instruc-
tions, and radiolabelled with [35S]-cysteine (Perkin Elmer). The
in vitro degradation assays were performed as described pre-
viously (Thomas et al., 2002), but using a 6 h incubation.
GST pulldown assays
These were performed as described previously (Massimi et al.,
2008).
Half-life assays
These were performed as described previously (Tomaic´ et al.,
2011).Pulldown and mass spectroscopy
HEK293 cells were transfected with plasmids expressing
HA-tagged E6 proteins (Massimi et al., 2008), or with empty
vector, by calcium precipitation. After overnight incubation the
cells were extracted in mass spectroscopy lysis buffer (50 mM
HEPES, pH 7.4, 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 0.25%
NP40) containing protease inhibitor cocktail I (Calbiochem) and
0.15 mg/ml dextran, as described before (Tomaic´ et al., 2009b).
The extracts were then incubated with anti-HA-agarose beads
(Sigma) for 3 h at 4 1C on a rotating wheel. The beads were
extensively washed, dried and subjected to mass spectroscopy.Acknowledgments
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